Trials (TAYS Cancer Centre Tampere University Hospital) - Revision history

Francine at 14:32, 14 December 2025

2025-12-14T14:32:47Z

← Older revision		Revision as of 14:32, 14 December 2025
Line 4:		Line 4:
	<span style="display:none">finlandcountry</span>		<span style="display:none">finlandcountry</span>
	Go back to [[TAYS Cancer Centre Tampere University Hospital]] page		Go back to [[TAYS Cancer Centre Tampere University Hospital]] page

			=== Trials: How to participate ===
			'''Contact information:''' [https://www.pirha.fi/palvelut/sairaalat-tays/syopa/syopatutkimukset Click here to access].


	'''NCTID''': NCT04736706		'''NCTID''': NCT04736706
Line 103:		Line 107:
	<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>		<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
	<span style="display:none">hasCancerType::unknown</span>		<span style="display:none">hasCancerType::unknown</span>
			<span style="display:none">isTrial</span>

Lucas: Update categories.

2025-12-06T12:42:25Z

Update categories.

← Older revision		Revision as of 12:42, 6 December 2025
Line 82:		Line 82:
	<span style="display:none">hasTrialTitle::A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer</span>		<span style="display:none">hasTrialTitle::A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer</span>
	<span style="display:none">hasTrialTitle::Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis</span>		<span style="display:none">hasTrialTitle::Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis</span>
			<span style="display:none">hasCancerType::C00-D48: All neoplasms</span>
			<span style="display:none">hasCancerType::C00-C97: All cancer types</span>
			<span style="display:none">hasCancerType::C00-C14: Mouth/throat cancers</span>
			<span style="display:none">hasCancerType::C15-C26: Digestive system cancers</span>
			<span style="display:none">hasCancerType::C30-C39: Lung/chest cancers</span>
			<span style="display:none">hasCancerType::C40-C41: Bone cancers</span>
			<span style="display:none">hasCancerType::C43-C44: Skin cancers/melanoma</span>
			<span style="display:none">hasCancerType::C45-C49: Soft tissue cancer</span>
			<span style="display:none">hasCancerType::C50: Breast cancer</span>
			<span style="display:none">hasCancerType::C51-C58: Female genitalia cancers</span>
			<span style="display:none">hasCancerType::C60-C63: Male genitalia cancer</span>
			<span style="display:none">hasCancerType::C64-C68: Urinary system cancers</span>
			<span style="display:none">hasCancerType::C69-C72: Eye and brain cancer</span>
			<span style="display:none">hasCancerType::C73-C75: Thyroid and other gland cancers</span>
			<span style="display:none">hasCancerType::C76-C80: Cancers of unknown or unspecified areas</span>
			<span style="display:none">hasCancerType::C81-C96: Cancers of the blood and immune system</span>
			<span style="display:none">hasCancerType::C97-C97: Cancers in multiple locations from the start</span>
			<span style="display:none">hasCancerType::D00-D09: Early-stage cancers not yet spread</span>
			<span style="display:none">hasCancerType::D10-D36: Benign tumour</span>
			<span style="display:none">hasCancerType::D37-D48: Growths of uncertain nature</span>
			<span style="display:none">hasCancerType::unknown</span>

Francine at 20:29, 2 December 2025

2025-12-02T20:29:42Z

← Older revision		Revision as of 20:29, 2 December 2025
Line 2:		Line 2:
	<span style="display:none">forproviders</span>		<span style="display:none">forproviders</span>
	<span style="display:none">forresearchers</span>		<span style="display:none">forresearchers</span>
	<span style="display:none">~~finland~~</span>		<span style="display:none">finlandcountry</span>
	Go back to [[TAYS Cancer Centre Tampere University Hospital]] page		Go back to [[TAYS Cancer Centre Tampere University Hospital]] page

Lucas: Update categories.

2025-12-02T14:00:59Z

Update categories.

← Older revision		Revision as of 14:00, 2 December 2025
Line 1:		Line 1:
	{{forpatients}}		<span style="display:none">forpatients</span>
	{{forproviders}}		<span style="display:none">forproviders</span>
	{{forresearchers}}		<span style="display:none">forresearchers</span>
	{{finland}}		<span style="display:none">finland</span>
	Go back to [[TAYS Cancer Centre Tampere University Hospital]] page		Go back to [[TAYS Cancer Centre Tampere University Hospital]] page

Line 75:		Line 75:
	'''Recruitment Status''': RECRUITING		'''Recruitment Status''': RECRUITING
	'''Condition''': Lymphoma, Large B-Cell, Diffuse		'''Condition''': Lymphoma, Large B-Cell, Diffuse
			<span style="display:none">hasTrialTitle::A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)</span>
			<span style="display:none">hasTrialTitle::Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer</span>
			<span style="display:none">hasTrialTitle::A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab</span>
			<span style="display:none">hasTrialTitle::A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression</span>
			<span style="display:none">hasTrialTitle::Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)</span>
			<span style="display:none">hasTrialTitle::A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer</span>
			<span style="display:none">hasTrialTitle::Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis</span>

Victor at 23:59, 5 November 2024

2024-11-05T23:59:34Z

← Older revision		Revision as of 23:59, 5 November 2024
Line 2:		Line 2:
	{{forproviders}}		{{forproviders}}
	{{forresearchers}}		{{forresearchers}}
			{{finland}}
	Go back to [[TAYS Cancer Centre Tampere University Hospital]] page		Go back to [[TAYS Cancer Centre Tampere University Hospital]] page

Francine at 15:23, 4 January 2024

2024-01-04T15:23:29Z

← Older revision		Revision as of 15:23, 4 January 2024
Line 5:		Line 5:

	'''NCTID''': NCT04736706		'''NCTID''': NCT04736706
	'''Title''': A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)		'''Title''': [[hasTrialTitle::A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)]]
	'''Study Summary''': The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.		'''Study Summary''': The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.
	'''Sponsor''': Merck Sharp & Dohme LLC		'''Sponsor''': Merck Sharp & Dohme LLC
Line 15:		Line 15:
	'''Condition''': Carcinoma, Renal Cell		'''Condition''': Carcinoma, Renal Cell
	'''NCTID''': NCT03155997		'''NCTID''': NCT03155997
	'''Title''': Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer		'''Title''': [[hasTrialTitle::Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer]]
	'''Study Summary''': The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.		'''Study Summary''': The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.
	'''Sponsor''': Eli Lilly and Company		'''Sponsor''': Eli Lilly and Company
Line 25:		Line 25:
	'''Condition''': Breast Cancer		'''Condition''': Breast Cancer
	'''NCTID''': NCT04770896		'''NCTID''': NCT04770896
	'''Title''': A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab		'''Title''': [[hasTrialTitle::A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab]]
	'''Study Summary''': This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have progressed on prior systemic treatment with atezolizumab plus bevacizumab combination.		'''Study Summary''': This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have progressed on prior systemic treatment with atezolizumab plus bevacizumab combination.
	'''Sponsor''': Hoffmann-La Roche		'''Sponsor''': Hoffmann-La Roche
Line 35:		Line 35:
	'''Condition''': Unresectable Hepatocellular Carcinoma		'''Condition''': Unresectable Hepatocellular Carcinoma
	'''NCTID''': NCT05325866		'''NCTID''': NCT05325866
	'''Title''': A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression		'''Title''': [[hasTrialTitle::A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression]]
	'''Study Summary''': The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.		'''Study Summary''': The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
	'''Sponsor''': Amgen		'''Sponsor''': Amgen
Line 45:		Line 45:
	'''Condition''': Solid Tumors		'''Condition''': Solid Tumors
	'''NCTID''': NCT03142334		'''NCTID''': NCT03142334
	'''Title''': Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)		'''Title''': [[hasTrialTitle::Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)]]
	'''Study Summary''': The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in the adjuvant treatment of adult participants who have undergone nephrectomy and have intermediate-high risk, high risk, or M1 no evidence of disease (M1 NED) renal cell carcinoma (RCC) with clear cell component. The primary study hypothesis is that pembrolizumab is superior to placebo with respect to Disease-free Survival (DFS) as assessed by the Investigator in male and female participants with intermediate-high risk, high risk and M1 NED RCC.		'''Study Summary''': The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in the adjuvant treatment of adult participants who have undergone nephrectomy and have intermediate-high risk, high risk, or M1 no evidence of disease (M1 NED) renal cell carcinoma (RCC) with clear cell component. The primary study hypothesis is that pembrolizumab is superior to placebo with respect to Disease-free Survival (DFS) as assessed by the Investigator in male and female participants with intermediate-high risk, high risk and M1 NED RCC.
	'''Sponsor''': Merck Sharp & Dohme LLC		'''Sponsor''': Merck Sharp & Dohme LLC
Line 55:		Line 55:
	'''Condition''': Renal Cell Carcinoma		'''Condition''': Renal Cell Carcinoma
	'''NCTID''': NCT05171777		'''NCTID''': NCT05171777
	'''Title''': A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer		'''Title''': [[hasTrialTitle::A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer]]
	'''Study Summary''': This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC. Two populations will be included: participants with resected Stage II, IIIA, and selected IIIB (T3-N2) NSCLC who have completed adjuvant platinum-based chemotherapy without evidence of disease relapse/recurrence, and chemotherapy-naïve participants with Stage IV NSCLC. The study will evaluate participant- and healthcare professionals (HCP)-reported preference for atezolizumab subcutaneous (SC) compared with atezolizumab intravenous (IV).		'''Study Summary''': This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC. Two populations will be included: participants with resected Stage II, IIIA, and selected IIIB (T3-N2) NSCLC who have completed adjuvant platinum-based chemotherapy without evidence of disease relapse/recurrence, and chemotherapy-naïve participants with Stage IV NSCLC. The study will evaluate participant- and healthcare professionals (HCP)-reported preference for atezolizumab subcutaneous (SC) compared with atezolizumab intravenous (IV).
	'''Sponsor''': Hoffmann-La Roche		'''Sponsor''': Hoffmann-La Roche
Line 65:		Line 65:
	'''Condition''': Non-small Cell Lung Cancer		'''Condition''': Non-small Cell Lung Cancer
	'''NCTID''': NCT03293173		'''NCTID''': NCT03293173
	'''Title''': Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis		'''Title''': [[hasTrialTitle::Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis]]
	'''Study Summary''': This study is testing whether stratification of the patients according to biological risk factors for different treatment groups will improve the outcome of patients with clinically high diffuse large B-cell lymphoma (DLBCL).		'''Study Summary''': This study is testing whether stratification of the patients according to biological risk factors for different treatment groups will improve the outcome of patients with clinically high diffuse large B-cell lymphoma (DLBCL).
	'''Sponsor''': Nordic Lymphoma Group		'''Sponsor''': Nordic Lymphoma Group

Francine: Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to TAYS Cancer Centre Tampere University Hospital page '''NCTID''': NCT04736706 '''Title''': A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) '''Study Summary''': The goal of..."

2023-12-01T21:17:56Z

Created page with "{{forpatients}} {{forproviders}} {{forresearchers}} Go back to TAYS Cancer Centre Tampere University Hospital page '''NCTID''': NCT04736706 '''Title''': A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) '''Study Summary''': The goal of..."

New page

{{forpatients}}
{{forproviders}}
{{forresearchers}}
Go back to [[TAYS Cancer Centre Tampere University Hospital]] page

'''NCTID''': NCT04736706
'''Title''': A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
'''Study Summary''': The goal of this study is to evaluate the efficacy and safety of pembrolizumab plus belzutifan plus lenvatinib or pembrolizumab/quavonlimab plus lenvatinib versus pembrolizumab plus lenvatinib as first-line treatment in participants with advanced clear cell renal cell carcinoma (ccRCC). The primary hypotheses are (1) pembrolizumab plus belzutifan plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to progression-free survival (PFS) and overall survival (OS), in advanced ccRCC participants; and (2) pembrolizumab/quavonlimab plus lenvatinib is superior to pembrolizumab plus lenvatinib with respect to PFS and OS, in advanced ccRCC participants.
'''Sponsor''': Merck Sharp & Dohme LLC
'''Intervention''': Pembrolizumab
'''Start Date''': 2021-04-14
'''Last Updated''': 2023-11-24
'''Number of Patients''': 1653
'''Recruitment Status''': RECRUITING
'''Condition''': Carcinoma, Renal Cell
'''NCTID''': NCT03155997
'''Title''': Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer
'''Study Summary''': The purpose of this study is to evaluate the safety and efficacy of the study drug abemaciclib in participants with high risk, node positive, early stage, hormone receptor positive (HR+), human epidermal receptor 2 negative (HER2-), breast cancer.
'''Sponsor''': Eli Lilly and Company
'''Intervention''': Abemaciclib
'''Start Date''': 2017-07-12
'''Last Updated''': 2023-07-14
'''Number of Patients''': 5637
'''Recruitment Status''': ACTIVE_NOT_RECRUITING
'''Condition''': Breast Cancer
'''NCTID''': NCT04770896
'''Title''': A Study of Atezolizumab With Lenvatinib or Sorafenib Versus Lenvatinib or Sorafenib Alone in Hepatocellular Carcinoma Previously Treated With Atezolizumab and Bevacizumab
'''Study Summary''': This is a Phase III, open-label, multicenter, randomized, two-arm study designed to evaluate the efficacy and safety of atezolizumab plus either lenvatinib or sorafenib versus lenvatinib or sorafenib alone in participants with locally advanced or metastatic Hepatocellular Carcinoma (HCC) who have progressed on prior systemic treatment with atezolizumab plus bevacizumab combination.
'''Sponsor''': Hoffmann-La Roche
'''Intervention''': Atezolizumab
'''Start Date''': 2021-04-26
'''Last Updated''': 2023-11-13
'''Number of Patients''': 554
'''Recruitment Status''': RECRUITING
'''Condition''': Unresectable Hepatocellular Carcinoma
'''NCTID''': NCT05325866
'''Title''': A Study Evaluating Bemarituzumab in Solid Tumors With Fibroblast Growth Factor Receptor 2b (FGFR2b) Overexpression
'''Study Summary''': The primary objectives of this study are to observe the safety and tolerability of bemarituzumab and to evaluate preliminary antitumor activity.
'''Sponsor''': Amgen
'''Intervention''': Bemarituzumab
'''Start Date''': 2022-09-23
'''Last Updated''': 2023-11-09
'''Number of Patients''': 303
'''Recruitment Status''': RECRUITING
'''Condition''': Solid Tumors
'''NCTID''': NCT03142334
'''Title''': Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)
'''Study Summary''': The purpose of this study is to evaluate the safety and efficacy of pembrolizumab (MK-3475) in the adjuvant treatment of adult participants who have undergone nephrectomy and have intermediate-high risk, high risk, or M1 no evidence of disease (M1 NED) renal cell carcinoma (RCC) with clear cell component. The primary study hypothesis is that pembrolizumab is superior to placebo with respect to Disease-free Survival (DFS) as assessed by the Investigator in male and female participants with intermediate-high risk, high risk and M1 NED RCC.
'''Sponsor''': Merck Sharp & Dohme LLC
'''Intervention''': Pembrolizumab
'''Start Date''': 2017-06-09
'''Last Updated''': 2023-06-29
'''Number of Patients''': 994
'''Recruitment Status''': ACTIVE_NOT_RECRUITING
'''Condition''': Renal Cell Carcinoma
'''NCTID''': NCT05171777
'''Title''': A Study to Evaluate Participant and Healthcare Professional Reported Preference for Subcutaneous Atezolizumab Compared With Intravenous Atezolizumab Formulation in Participants With Non-Small Cell Lung Cancer
'''Study Summary''': This is a Phase II, randomized, multi-center, multinational, open-label, cross-over study in adult participants with PD-L1-positive NSCLC. Two populations will be included: participants with resected Stage II, IIIA, and selected IIIB (T3-N2) NSCLC who have completed adjuvant platinum-based chemotherapy without evidence of disease relapse/recurrence, and chemotherapy-naïve participants with Stage IV NSCLC. The study will evaluate participant- and healthcare professionals (HCP)-reported preference for atezolizumab subcutaneous (SC) compared with atezolizumab intravenous (IV).
'''Sponsor''': Hoffmann-La Roche
'''Intervention''': Atezolizumab
'''Start Date''': 2022-04-04
'''Last Updated''': 2023-11-13
'''Number of Patients''': 176
'''Recruitment Status''': ACTIVE_NOT_RECRUITING
'''Condition''': Non-small Cell Lung Cancer
'''NCTID''': NCT03293173
'''Title''': Biomarker Driven Intensified ChemoImmunotherapy With Early CNS Prophylaxis
'''Study Summary''': This study is testing whether stratification of the patients according to biological risk factors for different treatment groups will improve the outcome of patients with clinically high diffuse large B-cell lymphoma (DLBCL).
'''Sponsor''': Nordic Lymphoma Group
'''Intervention''': R-CHOEP
'''Start Date''': 2017-08-04
'''Last Updated''': 2020-03-04
'''Number of Patients''': 120
'''Recruitment Status''': RECRUITING
'''Condition''': Lymphoma, Large B-Cell, Diffuse